SERUM CYTOKINE AND ADIPOKINE LEVELS IN PATIENTS WITH GOUT, THEIR ASSOCIATION WITH COMORBIDITY
DOI:
https://doi.org/10.11603/1811-2471.2023.v.i1.13732Keywords:
gout, comorbidity, cytokines, interleukin, adiponectin, leptin, inflammationAbstract
SUMMARY. Gout is a common, recurrent and potentially destructive arthritis associated with cardiometabolic-renal diseases. However, the underlying mechanisms of a high comorbidity burden are still not elucidated.
The aim – to analyze circulating levels of interleukin-1 beta (IL-1β), IL-6, IL-8, IL-10, leptin (L), adiponectin (A), A/L ratio, and determine their relationship with the gout-specifically modified Rheumatic Diseases Comorbidity Index (mRDCI) in patients with gout.
Material and Methods. This prospective study included 136 male patients with gout. The patients were divided into 4 subgroups based on the mRDCI values (0, 1–2, 3–4, and ≥5 points): 20 patients without comorbidities, 28 – with low сomorbidity index (CI), 62 – moderate CI, and 26 - high CI, respectively. The control group consisted of 31 practically healthy people. The serum levels of IL-1β, IL-6, IL-8, IL-10, adiponectin, and leptin were determined using an enzyme-linked immunosorbent assay. For a comprehensive assessment of dysadipokinemia we used the A/L ratio (with Adpn concentrations expressed in μg/ml and Lep levels in ng/ml).
Results. The serum levels of IL-6 were exceeded by 5.16 times in patients with gout in comparison with the control group, as well as IL-8 – by 4.05 times, IL-10 – by 2.7 times, IL-1β – by 2.6 times, leptin – by 2.3 times. Meanwhile, the A/L ratio was 4.2 times lower compared to the control group and the circulating adiponectin levels – 1.7 times (for all cytokines and adipokines p<0.001). We found a persistent and significant trend towards an increase in the serum levels of IL-1β, IL-6, IL-8, and leptin, while a decrease in the levels of IL-10, adiponectin, and the A/L ratio between mRDCI subgroups in the direction from the one without comorbidities to the one with high CI (p<0.001) in patients with gout.
Conclusion. An increase in serum levels of pro-inflammatory IL-1β, IL-6, IL-8, leptin, and a decrease in anti-inflammatory IL-10, adiponectin, the A/L ratio reflecting inflammatory burden in patients with higher mRDCI.
References
Dalbeth, N., Gosling, A.L., Gaffo, A., & Abhishek, A. (2021). Gout. The Lancet, 397(10287), 1843-1855. DOI: 10.1016/s0140-6736(21)00569-9.
Choi, H.K., McCormick, N., & Yokose, C. (2022). Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care. Nat. Rev. Rheumatol., 18(2), 97-111. DOI: 10.1038/s41584-021-00725-9.
Ahmed, S., Gasparyan, A.Y., & Zimba, O. (2021). Comorbidities in rheumatic diseases need special consideration during the COVID-19 pandemic. Rheumatol. Int., 41(2), 243-256. DOI: 10.1007/s00296-020-04764-5.
Chandratre, P., Mallen, C., Richardson, J., Muller, S., Hider, S., Rome, K., Blagojevic-Bucknall, M., & Roddy, E. (2018). Health-related quality of life in gout in primary care: Baseline findings from a cohort study. Semin. Arthritis Rheum., 48(1), 61-69. DOI: 10.1016/j.semarthrit.2017.12.005.
Joosten, L.A.B., Crişan, T.O., Bjornstad, P., & Johnson, R.J. (2020). Asymptomatic hyperuricaemia: a silent activator of the innate immune system. Nat. Rev. Rheumatol., 16(2), 75-86. DOI: 10.1038/s41584-019-0334-3.
Kreiner, F.F., Kraaijenhof, J.M., von Herrath, M., Hovingh, G.K.K., & von Scholten, B.J. (2022). Interleukin 6 in diabetes, chronic kidney disease, and cardiovascular disease: mechanisms and therapeutic perspectives. Expert. Rev. Clin. Immunol., 18(4), 377-389. DOI: 10.1080/1744666X.2022. 2045952.
Scanu, A., Oliviero, F., Luisetto, R., Ramonda, R., Doria, A., Punzi, L., & Dayer, J.M. (2021). Effect of pathogenic crystals on the production of pro- and anti-inflammatory cytokines by different leukocyte populations. Immunobiology, 226(1), 152042. DOI: 10.1016/j.imbio.2020.152042.
Murakami, T., Nakaminami, Y., Takahata, Y., Hata, K., & Nishimura, R. (2022). Activation and Function of NLRP3 Inflammasome in Bone and Joint-Related Diseases. Int. J. Mol. Sci., 23(10), 5365. DOI: 10.3390/ijms23105365.
Cavalcanti, N.G., Marques, C.D., Lins, E. Lins, T.U., Pereira, M.C., Rêgo, M.J., … Pitta, M.G. (2016). Cytokine Profile in Gout: Inflammation Driven by IL-6 and IL-18? Immunological Investigations, 45(5), 383-395. DOI: 10.3109/ 08820139.2016.1153651.
Kienhorst, L.B., van Lochem, E., Kievit, W., Dalbeth, N., Merriman, M.E., Phipps-Green, A., … Radstake, T.R. (2015). Gout Is a Chronic Inflammatory Disease in Which High Levels of Interleukin-8 (CXCL8), Myeloid-Related Protein 8/Myeloid-Related Protein 14 Complex, and an Altered Proteome Are Associated With Diabetes Mellitus and Cardiovascular Disease. Arthritis Rheumatol., 67(12), 3303-3313. DOI: 10.1002/art.39318.
Leonardi, G.C., Accardi, G., Monastero, R., Nicoletti, F., & Libra, M. (2018). Ageing: from inflammation to cancer. Immun. Ageing, 15, 1. DOI: 10.1186/s12979-017-0112-5.
Zuo, L., Prather, E. R., Stetskiv, M., Garrison, D. E., Meade, J. R., Peace, T. I., & Zhou, T. (2019). Inflammaging and Oxidative Stress in Human Diseases: From Molecular Mechanisms to Novel Treatments. Int. J. Mol. Sci., 20(18), 4472. DOI: 10.3390/ijms20184472.
Wu, M., Tian, Y., Wang, Q., & Guo, C. (2020). Gout: a disease involved with complicated immunoinflammatory responses: a narrative review. Clin. Rheumatol., 39(10), 2849-2859. DOI: 10.1007/s10067-020-05090-8.
Zhang, T., Wang, G., Zheng, J., Li, S., & Xu, J. (2021). Profile of serum cytokine concentrations in patients with gouty arthritis. J. Int. Med. Res., 49(11), 3000605211055618. DOI: 10.1177/03000605211055618.
Rafey, M.F., Abdalgwad, R., O'Shea, P.M., Foy, S., Claffey, B., Davenport, C., O'Keeffe, D.T., & Finucane, F.M. (2022). Changes in the Leptin to Adiponectin Ratio Are Proportional to Weight Loss After Meal Replacement in Adults With Severe Obesity. Frontiers in Nutrition, 9, 845574. DOI:10.3389/fnut.2022.845574.
Orlova, I.V., Stanislavchuk, M.A., & Gunko, I.P. (2018). Dysadipokinemia in patients with gout and its association with the disease activity. Wiad. Lek., 71(2, 2), 289-294. PMID: 29786572.
Targońska-Stępniak, B., & Grzechnik, K. (2022). Adiponectin and Leptin as Biomarkers of Disease Activity and Metabolic Disorders in Rheumatoid Arthritis Patients. J. Inflamm. Res., 15, 5845-5855. DOI: 10.2147/JIR.S380642.
Zhao, S., Zhu, Y., Schultz, R. D., Li, N., He, Z., Zhang, Z., … Scherer, P. E. (2019). Partial Leptin Reduction as an Insulin Sensitization and Weight Loss Strategy. Cell Metab., 30(4), 706-719.e6. DOI: 10.1016/j.cmet.2019.08.005.
Zhao, S., Kusminski, C.M., & Scherer, P.E. (2021). Adiponectin, Leptin and Cardiovascular Disorders. Circ. Res., 128(1), 136-149. DOI: 10.1161/CIRCRESAHA.120.314458.
Frühbeck, G., Catalán, V., Rodríguez, A., Ramírez, B., Becerril, S., Salvador, J., Colina, I., & Gómez-Ambrosi, J. (2019). Adiponectin-leptin Ratio is a Functional Biomarker of Adipose Tissue Inflammation. Nutrients, 11(2), 454. DOI: 10.3390/nu11020454.
Neogi, T., Jansen, T.L., Dalbeth, N., Fransen, J., Schumacher, H.R., Berendsen, D., … Taylor, W.J. (2015). 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann. Rheum. Dis., 74(10), 1789-1798. DOI: 10.1136/annrheumdis-2015-208237.
Bağcı, A., Aksoy, F., Baş, H. A., Işık, İ. B., & Orhan, H. (2021). The effect of Systolic and diastolic blood pressure on Tp-e interval in patients divided according to World Health Organization classification for body mass index. Clin. Exp. Hypertens., 43(7), 642-646. DOI:10.1080/10641963.2021.1925684.
Stevens, P.E., Levin, A., & Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. (2013). Evaluation and management of chronic kidney disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2012 Clinical practice Guideline. Ann. Intern. Med., 158(11), 825-830. DOI: 10.7326/0003-4819-158-11-201306040-00007.
Spaetgens, B., Wijnands, J.M., van Durme, C., & Boonen, A. (2015). Content and construct validity of the Rheumatic Diseases Comorbidity Index in patients with gout. Rheumatology (Oxford), 54(9), 1659-1663. DOI: 10.1093/rheumatology/kev030.
Maravilla Domínguez, M.A., Zermeño González, M.L., Zavaleta Muñiz, E.R., Montes Varela, V. A., Irecta Nájera, C.A., Fajardo Robledo, N.S., & Zavaleta Muñiz, S.A. (2022). Inflammation and atherogenic markers in patients with type 2 diabetes mellitus. Clin. Investig. Arterioscler., 34(3), 105-112. DOI: 10.1016/j.arteri.2021.03.006.
Kreiner, F.F., Kraaijenhof, J.M., von Herrath, M., Hovingh, G.K.K., & von Scholten, B.J. (2022). Interleukin 6 in diabetes, chronic kidney disease, and cardiovascular disease: mechanisms and therapeutic perspectives. Expert. Rev. Clin. Immunol., 18(4), 377-389. DOI: 10.1080/ 1744666X.2022.2045952.
Ridker, P.M., MacFadyen, J.G., Thuren, T., & Libby, P. (2020). Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis. Eur. Heart J., 41(23), 2153-2163. DOI: 10.1093/eurheartj/ehz542.
Ridker, P.M., Everett, B.M., Thuren, T., MacFadyen, J.G., Chang, W.H., Ballantyne, C., … & CANTOS Trial Group (2017). Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N. Engl. J. Med., 377(12), 1119-1131. DOI: 10.1056/NEJMoa1707914.
Rojas, J.M., Avia, M., Martín, V., & Sevilla, N. (2017). IL-10: A Multifunctional Cytokine in Viral Infections. J. Immunol. Res., 2017, 6104054. DOI: 10.1155/2017/6104054.
Patterson, B.K., Guevara-Coto, J., Yogendra, R., Francisco, E.B., Long, E., Pise, A., …, & Mora-Rodríguez, R.A. (2021). Immune-Based Prediction of COVID-19 Severity and Chronicity Decoded Using Machine Learning. Front. Immunol., 12, 700782. DOI: 10.3389/fimmu.2021.700782.
Diaz-Torne, C., Ortiz, M.A., Garcia-Guillen, A., Jeria-Navarro, S., Sainz, L., Fernandez-Sanchez, S., Corominas, H., & Vidal, S. (2021). The inflammatory role of silent urate crystal deposition in intercritical gout. Rheumatology (Oxford), 60(11), 5463-5472. DOI: 10.1093/rheumatology/keab335.
Frühbeck, G., Catalán, V., Rodríguez, A., & Gómez-Ambrosi, J. (2018). Adiponectin-leptin ratio: A promising index to estimate adipose tissue dysfunction. Relation with obesity-associated cardiometabolic risk. Adipocyte, 7(1), 57–62. DOI: 10.1080/21623945.2017.1402151.
Tonon, F., Di Bella, S., Giudici, F., Zerbato, V., Segat, L., Koncan, R., … & Bernardi, S. (2022). Discriminatory Value of Adiponectin to Leptin Ratio for COVID-19 Pneumonia. Int. J. Endocrinol., 2022, 9908450. DOI: 10.1155/ 2022/9908450.
